27.44
price up icon0.73%   0.20
after-market Handel nachbörslich: 26.73 -0.71 -2.59%
loading
Schlusskurs vom Vortag:
$27.24
Offen:
$27.25
24-Stunden-Volumen:
945.89K
Relative Volume:
1.51
Marktkapitalisierung:
$2.17B
Einnahmen:
$384.10M
Nettoeinkommen (Verlust:
$-9.07M
KGV:
-196.00
EPS:
-0.14
Netto-Cashflow:
$11.10M
1W Leistung:
-3.31%
1M Leistung:
-1.72%
6M Leistung:
+37.61%
1J Leistung:
+48.73%
1-Tages-Spanne:
Value
$26.89
$27.97
1-Wochen-Bereich:
Value
$26.89
$28.86
52-Wochen-Spanne:
Value
$17.82
$30.69

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name
Firmenname
Kiniksa Pharmaceuticals International Plc
Name
Telefon
(781) 431-9100
Name
Adresse
23 OLD BOND STREET, FLOOR 3, LONDON
Name
Mitarbeiter
315
Name
Twitter
@kiniksa
Name
Nächster Verdiensttermin
2024-10-29
Name
Neueste SEC-Einreichungen
Name
KNSA's Discussions on Twitter

Vergleichen Sie KNSA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
KNSA
Kiniksa Pharmaceuticals International Plc
27.44 2.17B 384.10M -9.07M 11.10M -0.14
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
10.36 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
159.08 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.26 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.42 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
17.05 20.17B 16.54B -1.64B 749.00M -1.45

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-13 Eingeleitet Citigroup Buy
2024-09-13 Eingeleitet Jefferies Buy
2024-05-03 Eingeleitet Wells Fargo Overweight
2020-06-29 Bestätigt BofA Securities Buy
2020-04-01 Eingeleitet BofA/Merrill Buy
2019-03-11 Eingeleitet Barclays Overweight
2018-12-12 Bestätigt Wedbush Outperform
2018-06-19 Eingeleitet JMP Securities Mkt Outperform
Alle ansehen

Kiniksa Pharmaceuticals International Plc Aktie (KNSA) Neueste Nachrichten

pulisher
Jun 18, 2025

Kiniksa pharma COO Tessari sells $489k in shares By Investing.com - Investing.com South Africa

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Selling: Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) COO Sells 17,300 Shares of Stock - MarketBeat

Jun 18, 2025
pulisher
Jun 16, 2025

Kiniksa Pharmaceuticals: Arcalyst Performs, KPL-387 Advancing Fast (NASDAQ:KNSA) - Seeking Alpha

Jun 16, 2025
pulisher
Jun 13, 2025

Lewis & Ellis acquires Huggins Actuarial Services - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

UK court rules insurers must pay more than $1bn for planes seized in Russia - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Payment software firm Payrails raises $32m in funding - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

WRAP EU leads textiles extended producer responsibility talks - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Canary raises $80m to fuel expansion in hospitality AI - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

FirmaPak expands global footprint with Lighthouse Packaging acquisition - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves label expansion of AbbVie hepatitis C therapy - Yahoo

Jun 13, 2025
pulisher
Jun 13, 2025

Israel attacks Iran, stock market futures tumble - Yahoo

Jun 13, 2025
pulisher
Jun 12, 2025

Green Bay Packaging Executive Vice President Bryan Hollenbach to retire in August - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Jio BlackRock gets nod to operate as investment adviser in India - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Output of key food commodities “on course for new records” – FAO - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Why Oklo Stock Dropped on Thursday - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Medtech leaders unite on Capitol Hill to fight tariffs - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Actabl launches new ProfitSword digital night audit feature for hotels - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

UCC Holding and Ashghal launch 3D Printed Schools Project in Qatar - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Grant Thornton Advisors appoints new COO - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Biggby Coffee unveils first brand refresh - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Prime Drink Group’s bottling unit enters receivership - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Del Taco expands to Louisville with new franchise agreement - Yahoo

Jun 12, 2025
pulisher
Jun 12, 2025

Trump’s Treasury Sec Admits It’s Another TACO Day With China - Yahoo

Jun 12, 2025
pulisher
Jun 11, 2025

Hakkers and Paebbl introduce carbon-storing solution at Port of Rotterdam - Yahoo

Jun 11, 2025
pulisher
Jun 11, 2025

Mistral unveils Europe’s first AI reasoning model Magistral - Yahoo

Jun 11, 2025
pulisher
Jun 10, 2025

Costco Announces Important Change for Certain Members Starting June 30 - Yahoo

Jun 10, 2025
pulisher
Jun 10, 2025

Transcript : Kiniksa Pharmaceuticals International, plc Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 08 - MarketScreener

Jun 10, 2025
pulisher
Jun 10, 2025

MSD receives FDA approval for Enflonsia to prevent RSV - Yahoo

Jun 10, 2025
pulisher
Jun 05, 2025

Kiniksa Pharmaceuticals Executives Sell Shares - TradingView

Jun 05, 2025
pulisher
Jun 05, 2025

KNSA stock soars to 52-week high, hits $29.71 amid robust gains - Investing.com UK

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa sets Phase 2/3 trial for heart drug KPL-387 - Investing.com Nigeria

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | K - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design Of Planned Phase 2/3 Clinical Trial Of Kpl-387 In Recurrent Pericarditis - marketscreener.com

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design of Planned Phase 2/3 Clinical Trial of KPL-387 in Recurrent Pericarditis | KNSA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa (KNSA) to Launch Phase 2/3 Trial for KPL-387 in 2025 | KNSA Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa Pharmaceuticals Announces Trial Design of Planned - GlobeNewswire

Jun 05, 2025
pulisher
Jun 05, 2025

Kiniksa Advances Revolutionary Monthly Dosing Treatment for Recurrent Pericarditis: Phase 2/3 Trial Details Released - Stock Titan

Jun 05, 2025
pulisher
Jun 04, 2025

Louis Vuitton files lawsuit against Portuguese liqueur start-up over branding rights - Yahoo

Jun 04, 2025
pulisher
Jun 03, 2025

Kiniksa Pharmaceuticals Annual Shareholders Meeting Decisions - TipRanks

Jun 03, 2025
pulisher
May 29, 2025

Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Kiniksa Pharmaceuticals to Present at Jefferies and Goldman Sachs Healthcare Conferences in June - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% H - GuruFocus

May 29, 2025
pulisher
May 28, 2025

Kiniksa Pharmaceuticals International PLC (KNSA) Trading 4.13% Higher on May 28 - GuruFocus

May 28, 2025
pulisher
May 24, 2025

Beloved Fast Food Chain Makes Telling Move After Closing Hundreds of Locations - Yahoo

May 24, 2025
pulisher
May 20, 2025

Okika Devices relocates HQ to Colorado Springs - Yahoo

May 20, 2025
pulisher
May 17, 2025

Maryland loses Triple-A bond rating - Yahoo

May 17, 2025
pulisher
May 14, 2025

Dimensional Fund Advisors LP Acquires 29,300 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) - MarketBeat

May 14, 2025
pulisher
May 09, 2025

Kiniksa Pharmaceuticals CEO sells shares worth $218,866 By Investing.com - Investing.com Nigeria

May 09, 2025
pulisher
May 09, 2025

Kiniksa Pharmaceuticals CEO sells shares worth $218,866 - Investing.com Australia

May 09, 2025
pulisher
May 09, 2025

Capra Bank recognized as fastest growing in recent study - Yahoo

May 09, 2025
pulisher
May 05, 2025

Kiniksa Pharmaceuticals: Making Steady Progress (NASDAQ:KNSA) - Seeking Alpha

May 05, 2025

Finanzdaten der Kiniksa Pharmaceuticals International Plc-Aktie (KNSA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Kiniksa Pharmaceuticals International Plc-Aktie (KNSA) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Tessari Eben
CHIEF OPERATING OFFICER
Jun 16 '25
Sale
28.28
17,300
489,244
61,563
$14.72
price up icon 2.01%
$9.34
price up icon 1.74%
$129.40
price up icon 1.09%
$295.22
price up icon 1.48%
drug_manufacturers_specialty_generic RDY
$14.88
price down icon 0.40%
$17.05
price up icon 2.46%
Kapitalisierung:     |  Volumen (24h):